Research Analysts Set Expectations for Chemours Q1 Earnings

The Chemours Company (NYSE:CC) – Research analysts at Zacks Research cut their Q1 2027 EPS estimates for shares of Chemours in a note issued to investors on Wednesday, July 22nd. Zacks Research analyst Team now anticipates that the specialty chemicals company will post earnings per share of $0.39 for the quarter, down from their prior forecast of $0.41. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $1.18 per share. Zacks Research also issued estimates for Chemours’ Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

A number of other research firms also recently weighed in on CC. Morgan Stanley raised their price target on Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Monday, May 11th. Royal Bank Of Canada boosted their price target on Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Alembic Global Advisors reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Chemours in a research report on Wednesday, May 13th. Mizuho cut their price objective on shares of Chemours from $30.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Chemours from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Chemours has a consensus rating of “Moderate Buy” and a consensus target price of $24.10.

Chemours Stock Performance

Shares of NYSE CC opened at $17.50 on Thursday. The business’s 50-day moving average price is $20.47 and its two-hundred day moving average price is $19.89. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87. Chemours has a one year low of $10.44 and a one year high of $28.67. The company has a market capitalization of $2.63 billion, a P/E ratio of -6.63 and a beta of 1.41.

Chemours (NYSE:CC) last posted its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.10. The business had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. Chemours’s revenue for the quarter was up 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.13 earnings per share.

Hedge Funds Weigh In On Chemours

A number of institutional investors have recently modified their holdings of the company. Parallel Advisors LLC lifted its stake in shares of Chemours by 10.9% during the first quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock valued at $118,000 after acquiring an additional 527 shares during the period. Oregon Public Employees Retirement Fund lifted its position in Chemours by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock valued at $404,000 after purchasing an additional 600 shares during the period. PFG Investments LLC boosted its stake in shares of Chemours by 7.6% in the 4th quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock valued at $147,000 after purchasing an additional 883 shares during the last quarter. State of Alaska Department of Revenue boosted its stake in shares of Chemours by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock valued at $899,000 after purchasing an additional 932 shares during the last quarter. Finally, Man Group plc grew its position in shares of Chemours by 0.4% during the 2nd quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after buying an additional 979 shares during the period. Institutional investors own 76.26% of the company’s stock.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.0%. The ex-dividend date was Friday, May 15th. Chemours’s dividend payout ratio (DPR) is -13.26%.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.